Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 920 adults with atopic dermatitis (eczema) across two treatment groups in the first phase: 462 people received dupilumab and 458 received upadacitinib. The trial was designed in two back-to-back periods running from the start to Week 16, and then from Week 16 to Week 32, with some participants switching or continuing treatment in the second period. The main thing the trial was measuring was how many people, by Week 16, achieved both a 90% or greater reduction in a standard eczema severity score (called EASI, which rates skin redness, thickness, scratching marks, and skin hardening on a scale of 0 to 72) and also reported their worst itch as zero or one out of ten on a rating scale. The reported data shows that for the primary measure at Week 16 — achieving both the near-complete skin clearance and near-zero itch score together — 8.9% of participants in the dupilumab group and 19.9% in the upadacitinib group reached that combined goal. Looking at skin clearance alone (the 90% reduction in the EASI score), the reported figures were 22.5% for dupilumab and 40.8% for upadacitinib. For itch specifically, 15.5% of the dupilumab group and 30.2% of the upadacitinib group reported their worst itch dropping to nearly none (a score of 0 or 1) by Week 16. Earlier in the trial, at Week 4, those itch figures were 2.8% and 16.1% respectively, and at Week 2 they were 1.3% and 7.7%. The reported data also shows that 38.1% of dupilumab participants and 54.7% of upadacitinib participants who started with moderate-to-severe itch saw their itch score drop by at least 4 points by Week 16. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 41533220) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Eczema Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with chronic atopic dermatitis (eczema) with symptoms that started at least 3 years before the study begins, and your condition meets a specific set of recognised diagnostic guidelines (confirm with trial site).
- Your eczema is rated as moderate to severe based on standard medical scoring tools that measure how much of your body is affected and how severe the patches are.
- You experience significant itching on a regular basis, rated at least 4 out of 10 on a daily itch scale averaged over a week.
- You have already tried at least one other whole-body (systemic) treatment for your eczema and it did not work well enough, or your doctor has determined that other whole-body treatments are not suitable for you.
Who may not be able to join:
- You have had a significant problem with drug or alcohol misuse within the last 6 months (as judged by the study doctor).
- You have had an organ transplant and still need to take medication to prevent your body from rejecting it.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: ABBVIE INC., AbbVie
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
5 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Percentage of Participants Achieving a ≥ 90% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 90) and Worst Pruritus Numerical Rating Scale of 0 or 1 (WP-NRS 0/1) at Week 16
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.